Ongoing projects and patient cohorts

Mucosal measurements to target Mucosal therapies:

1. Right strategy, right population

Respiratory infections affect children worldwide, but their epidemiology, risk factors and healthcare context differ between populations and settings. Prevention and treatment strategies therefore cannot simply be transferred from one population to another.

We study respiratory infections across diverse global settings to identify which strategies work, for whom, and under which circumstances, with the aim of developing locally appropriate approaches for vulnerable children.

2. Respiratory samples as biosensor

Respiratory samples such as saliva provide a child-friendly window into what is happening at the site of infection. By measuring pathogens, proteins, antibodies and immune cells, we use these samples as biosensors of both infection and the mucosal immune response.

Our goal is to translate this information into better diagnosis, prediction of disease course and treatment decisions, ultimately bringing respiratory sampling into clinical practice.

3. Understanding mucosal immunity

The respiratory mucosa is our first line of defence against the pathogens we encounter every day. We study how antibodies, immune cells and the respiratory epithelium work together to protect children against respiratory infections, and why this protection sometimes fails. By combining mechanistic, translational and clinical research, we aim to turn this understanding into new strategies that strengthen mucosal protection for prevention and treatment of respiratory infections.

1. Right strategy, right population projects

Approach

January 2019 – YTD

Comparing co-trimoxazole with placebo treatment in children with recurrent respiratory tract infections in 15 Dutch hospitals.

CARE-READY

June 2026 – YTD

Caribbean Arboviral and Respiratory Epidemiology – Readiness for detection and action.

CARE-SAFE

March 2024 – February 2026

Advanced Caribbean surveillance and seasonal vaccination timing for pandemic preparedness.

CURE-VIR

September 2021 – YTD

Collaborative Understanding of REpuroposed drugs for VIRal respiratory infections.

IMPRESS

February 2020 – October 2021

IgA Prevalence in Recurrent Respiratory tract infections.

Nutri-Vac

August 2018 – April 2024

Impact of nutritional status on vaccine-induced immunity in children living in South Africa.

RISE

August 2022 – YTD

Respiratory Infections SMMC ENT.

RSV Roadmap CAS-islands

March 2026 – YTD

An implementation pathway for Curaçao, Aruba and Sint Maarten.

2. Respiratory samples as biosensor projects

BCG-Corona saliva study

March 2020 – July 2026

Health care workers in nine Dutch hospitals were randomised to BCG or placebo vaccination and donated blood and saliva for antibody assays.

COVID-Kids

April 2020 – June 2026

Clinical presentation, immunology, respiratory morbidity and transmission dynamics in South African children.

DIMER

March 2016 – YTD

Deficiency of Immunoglobulin A and Microbiome in Respiratory tract infections.

Muco-Kids

November 2024 – YTD

Mucosal surveillance and immunology of respiratory pathogens in South African children post the COVID-19 pandemic.

PAGE

January 2025 – YTD

Polyreactive antibodies in saliva and serum to assess respiratory infection risk and develop novel diagnostic biomarkers.

PEER-S

January 2019 – YTD

Effects of air pollution on mucosal respiratory health.

PRINDOUT

January 2025 – YTD

Prenatal infection effects on early development: brain, cognitive and behavioural outcome.

PRISM

October 2024 – YTD

Paediatric Respiratory Infections with Systemic and Mucosal Inflammation.

Respiratory Toolbox

June 2023 – YTD

Developing and validating an innovative toolset that allows future research on the development of the mucosal immune system in the first years of life.

VIP study

May 2012 – January 2021

Venezuela Immunisation against Pneumococci.

3. Understanding mucosal immunity projects

B-HIVe study

February 2026 – YTD

B-HIVe is an innovative research project aimed at discovering and developing broad-spectrum protective antibodies derived from people living with HIV.

CHERI-SPAR

March 2025 – YTD

Salivary Polyreactive Antibody Response in CHERI.

DIMEGA

March 2016 – May 2026

Deficiency of Immunoglobulin A and Microbiome in Respiratory tract infections Gut Analysis.

EMINENT

January 2023 – YTD

Early Mucosal Immunity in ENT samples.

SALIAC

March 2025 – YTD

SALiva Immunomarkers Assessment for COPD in children and adults.

SIPAD

February 2024 – YTD

Saliva antibodies Influencing Progression of Airway Disease in Primary Antibody Deficiency.

© Copyright Lilly Verhagen